pfizer glp 1 agonist Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies Focus on Glucagon-like Peptide-1 Target:
Description
The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro
The Risks: Unknown ingredients and contamination Incorrect dosages and life-threatening side effects No regulatory oversight or safety data Why This Is Critical: Patients are bypassing pharmacies and getting injections from sketchy online vendors This undermines real GLP1 therapies and can lead to serious harm As healthcare professionals, we must: Ask patients about the source of their medications Report adverse reactions to MedWatch Educate our patients about safe access and real prescriptions Lets advocate for ethical prescribing and responsible patient care in the GLP1 era
If you're not, this isn't a reason to start one
Stuck on semaglutide or tirzepatide
The global appetite for GLP-1 medications like Ozempic, Wegovy and Mounjaro have created something far more dangerous than a cultural trend
